p53 gene mutations and HPV infection in primary head and neck squamous cell carcinomas do not correlate with overall survival: A long term follow-up study

Journal of Oral Pathology and Medicine

Volumn 26, Issue 7, 1997, Pages 315-321

  Riethdorf, Sabine ^a   Friedrich, Reinhard E ^a   Ostwald, Christiane ^b   Barten, Malte ^b   Gogacz, Pawel ^b   Gundlach, Karsten K H ^b   Schlechte, Horst ^c   Becker, Jürgen ^c   Bregenzer, Thomas ^a   Riethdorf, Lutz ^a   Löning, Thomas ^a,d  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Head and neck squamous cell carcinoma (HNSCC); HPV; p53; Survival

Indexed keywords

EID: 8544224247     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.1997.tb00222.x     Document Type: Article

References (49)

1. LEVINE AJ, PERRY ME, CHANG A et al. The 1993 Walter Hubert Lecture: the role of p53 tumor-suppressor gene in tumorigenesis. Br J Cancer 1994; 69: 409-16.
2. CORDON-CARDO C. Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995; 147: 545-60.
3. KASTAN MB, ONKYEKWERE O, SIDRANSKY D, VOGELSTEIN B, CRAIG RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
4. FIELDS S, JANG SK. Presence of a potent transcription activating sequence in the p53 protein. Science 1990; 249: 1046-9.
5. CHO Y, GORINA S, JEFFREY PD, PAVLETICH NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346-55.
6. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B, HARRIS C. p53 mutations in human cancer. Science 1991; 253: 49-53.
7. PORTER PL, GOWN AM, KRAMP SG, COLTRETA MG. Wide-spread p53 overexpression in human malignant tumors: an immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol 1992; 140: 145-53.
8. PARKIN DM, LAARA E, MUIR CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988; 41: 184-97.
9. VOKES EE, WEICHSELBAUM RR, LIPPMAN SM, HONG WK. Head and neck cancer. N Engl J Med 1993; 328: 184-94.
10. OSTWALD C, MÜLLER P, BARTEN M, et al Human papillomavirus DNA in oral squamous cell carcinomas and normal mucosa. J Oral Pathol Med 1994; 23: 220-5.
11. BARTEN M, OSTWALD C, MILDE-LANGOSCH K, MÜLLER P; WUKASCH Y, LÖNING T. HPV DNA and p53 alterations in oropharyngeal carcinomas. Virchows Arch 1995; 427: 153-7.
12. FIELD JK. The role of oncogenes and tumour-suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma. J R Soc Med 1995; 88: 35P-9P.
13. AHOMADEGBE JC, BARROIS M, FOGEL S, et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of a correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995; 10: 1217-27.
14. SCHEFFNER M, WERNES BA, HUIBREGTSE JM, LEVINE AJ, HOWLEY PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-36.
15. WERNES BA, LEVINE AJ, HOWLEY PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248: 76-9
16. Li XQ, COFFINO P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol 1996; 70: 4509-16.
17. SNIJDERS PJF, VAN DEN BRULE AJC, MEIJER CJLM, WALBOOMERS JMM. Papillomaviruses and cancer of the upper digestive and respiratory tracts. Curr Top Microbiol Immunol 1994; 186: 177-98.
18. SNIJDERS PJF, SCHOLES AGM, HART CA, et al. Prevalence of mucosotropic human papillomaviruses in squamous-cell carcinomas of the head and neck. Int J Cancer 1996; 66: 464-9.
19. PARK DJ, WILCZYNSKI SP, PAQUETTE RL, MILLER CW, KOEFFLER HP. p53 mutations in HPV-negative cervical carcinoma. Oncogene 1994; 9: 205-10.
20. MILDE-LANGOSCH K, ALBRECHT K, JORAM S, GIESSING M, LÖNING T. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int J Cancer 1995; 63: 639-45.
21. CHIBA I, SHINDOH M, YASUDA M, et al. Mutations of the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity. Oncogene 1996; 12: 1663-68.
22. HARAF DJ, NODZENSKI E, BRACHMAN D, et al. Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clinic Cancer Res 1996; 2: 755-62.
23. HERMANEK P, SOBIN LH. TNM classification and malignant tumours. 4th edn. UICC International Union Against Cancer. Berlin: Springer-Verlag, 1992.
24. KAPPES S, MILDE-LANGOSCH K, KRESSIN P, et al. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J Cancer 1995; 64: 52-9.
25. SCHOLZ B, MILDE-LANGOSCH K, JUNG R, et al. Rapid screening for Tp53 mutations by temperature-gradient gel electrophoresis: a comparison with SSCP analysis. Human Mol Genet 1993; 2: 2155-8.
26. MANOS MM, TING Y, WRIGHT DK, LEWIS AJ, BROKER TR, WOLINSKY S. Use of polymerase-chain-reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 1989; 7: 209-14.
27. BAUER HM, GREER CE, MANOS MM. Determination of genital human papillomavirus infection by consensus PCR amplification. In: HERRINGTON CS, MCGEE JOD eds. Diagnostic molecular pathology: a practical approach. Oxford: Oxford Press, 1992; 131-52.
28. LAVIEILLE JP, BRAMBILLA E, RIVA-LAVIEILLE C, REYT E, CHARACHON R, BRAMBILLA C. Immunohistochemical detection of p53 protein in preneoplastic lesions and squamous cell carcinoma of the head and neck. Acta Otolaryngol (Stockh) 1995; 115: 334-9.
29. HABUCHI T, TAKAHASHI R, YAMADA H, et al. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res 1993; 53: 3795-9.
30. PERWES-HUSSAIN S, AGUILAR F, CERUTTI P. Mutagenesis of codon 248 of the human p53 tumour suppressor gene by N-ethyl-N-nitrosurea. Oncogene 1994; 9: 13-8.
31. SAKAI E, TSUCHIDA N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 1992; 7: 927-33.
32. KIM MS, LI SL, BERTOLAMI CN, CHERRICK HM, PARK N-H. State of p53, Rb and DCC tumor suppressor genes in human oral cancer cell lines. Anticancer Res 1993; 13: 1405-14.
33. BOYLE JO, HAKIM J, KOCH W, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993; 53: 4477-80.
34. NYLANDER K, NILSSON P, MEHLE C, ROOS G. p53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck. Br J Cancer 1995; 71: 826-30.
35. MAO EJ, SCHWARTZ SM, DALING JR, ODA D, TICKMAN L, BECKMANN AM Human papillomaviruses and p53 mutations in normal, premalignant and malignant oral epithelia. Int J Cancer 1996; 69: 152-8.
36. PUISIEUX A, LIM S, GROOPMAN J, OZTURK M. Selective targeting of p53 gene mutational hot spots in human cancers by etiologically defined carcinogens. Cancer Res 1991; 51: 6185-9.
37. LOHMANN D, PÜTZ B, REICH U, BÖHM J, PRÄUER H, HÖFLER M. Mutational spectrum of the p53 gene in human small-cell lung cancer in relationship to clinicopathological data. Am J Path 1993; 142: 907-15.
38. FINLAY CA. Normal and malignant growth control by p53. In: BENZ CC, LIU ET eds. Oncogenes and tumuor suppressor genes in human malignancies. Boston: Academic Publishers, 1993; 327-44.
39. AWWAD S, JAROS E, SOMES J, LUNEC J. p53 overexpression in head and neck carcinoma and radiotherapy results. Int J Radiation Oncolog Biol Phys 1995; 34: 323-33.
40. SHINTANI S, YOSHIHAMA Y, EMILIO AR, MATSUMURA T. Overexpression of p53 is an early event in the tumorigenesis of oral squamous cell carcinomas. Anticancer Res 1995; 15: 305-8.
41. TSUJI T, MIMURA Y, WEN S, et al. The significance of PCNA and p53 protein in some oral tumors. Int J Oral Maxillofac Surg 1995; 24: 221-5.
42. SPANDIDOS DA, LILOGLOU T, FIELD JK. Prognostic significance of oncogenes and tumor suppressor genes in human malignancy. Stem Cells 1993; 11: 194-8.
43. MARTINAZZI M, CRIVELLI F, ZAMPATI C, MARTINAZZI S. Relationship between p53 expression and other prognostic factors in human breast carcinoma. Anatomic Pathol 1992; 100: 213-7.
44. RIETHDORF L, BEGEMANN C, RIETHDORF S, MILDE-LANGOSCH K, LÖNING T. Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature-gradient gel electrophoresis. Virchows Arch 1996; 428: 47-51.
45. MATSUDA H, KONISHI N, HIASA Y, et al. Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. J Oral Pathol Med 1996; 25: 232-8.
46. REGEZI JA, ZARBO RJ, REGEV E, PISANTY S, SILVERMAN S, GRAZIT D. p53 protein expression in sequential biopsies of oral dysplasias and in situ carcinomas. J Oral Pathol Med 1995; 24: 18-22.
47. WATLING DL, GOWN AM, COLTRERA MD. Overexpression of p53 in head and neck cancer. Head Neck 1992; 14: 437-44.
48. ZUR HAUSEN H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 1994; 186: 131-56.
49. FURIHATA M, OHTSUKI Y, OGOSHI S, TAKAHASHI A, TAMIYA T, OGATA T. Prognostic significance of human papillomavirus genomes (type-16,-18) and abberant expression of p53 protein in human esophageal cancer. Int J Cancer 1993; 54: 226-30.